Prasugrel Outperforms Clopidogrel In Head-To-Head Test For Recurrent Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly and Daiichi Sankyo await Sept. 26 FDA action date for anti-platelet drug slated to take on Bristol’s Plavix.
You may also be interested in...
Daiichi Sankyo Expands European Sales Presence By Hiring 130 Merck KGaA Reps
Goal is a 70/30 split of ROW and Japanese revenues, firm says.
Bristol Readies For Prasugrel’s Impact On Plavix, Files DPP-4 Inhibitor
Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)
Prasugrel Delay Shifts Focus To Possible August Advisory Committee
FDA extends user fee date for the novel anti-platelet drug to Sept. 26.